From Wisdom 2.0 2019 in San Francisco.
16:35 min
CLEAR ALL
French photographer Mathias de Lattre's project "Mother's Therapy" examines the relationship between mental illness and psychedelic therapies.
People of color are dealing with racism all the time, in large and small ways, and even dealing with racism in healthcare, even dealing with racism in therapy.
In the last two decades, researchers have started to reexamine psychedelics for their therapeutic potential. Though initial results seem promising, the research has a significant shortcoming: the lack of racial and ethnic diversity among research teams and study participants.
1
A new study finds widespread exclusion of minorities in psychedelic research.
We’re seeing an explosion of medical research into psychedelics. Psilocybin, or shrooms, to treat major depressive disorder. Ayahuasca, a psychotropic plant medicine from the Amazon, and ibogaine, a potent hallucinogen from Africa, to treat addiction. LSD for anxiety.
Through this treatment plan, the patient was able to “reconceptualize her trauma” and “was able to move through difficult memories and emotions rather than letting them consume her,” explained U of O associate professor, Monnica Williams.
These substances are being touted as a game-changing intervention for mental health. But it’s not clear if their promise will be accessible to all.
2
Could there be one factor that links together conflict, climate change, racism, anxiety and eating disorders?
Society has started to become more accepting of our work and MAPS’ goal of mainstreaming psychedelic medicine seems closer than ever to being achieved,” explains MAPS Policy and Advocacy Director Natalie Ginsberg, M.S.W., in an interview with Jessica Semaan of Seismic Sisters.
Badass women making waves in the psychedelic movement, from research to drug policy reform.